Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II trial is studying cetuximab to see how well it works in treating patients with persistent or recurrent cervical cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
Cervical Squamous Cell Carcinoma
Recurrent Cervical Cancer
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix|
- Progression-free survival [ Time Frame: At 6 months ] [ Designated as safety issue: No ]
- Objective tumor response assessed by Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: At 6 months ] [ Designated as safety issue: No ]
- Duration of progression-free survival [ Time Frame: From study entry until disease progression, death or date of last contact, up to 5 years ] [ Designated as safety issue: No ]
- Duration of objective response rate [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
- Frequency and severity of adverse effects as assessed by Common Terminology Criteria for Adverse Events version 3.0 [ Time Frame: Up to 5 years ] [ Designated as safety issue: Yes ]
- Duration of overall survival [ Time Frame: From study entry to death or the date of last contact, up to 5 years ] [ Designated as safety issue: No ]
|Study Start Date:||June 2007|
|Primary Completion Date:||January 2012 (Final data collection date for primary outcome measure)|
Experimental: Treatment (cetuximab)
Patients receive cetuximab IV over 120 minutes on day 1.
I. To assess the activity of cetuximab for patients with persistent or recurrent carcinoma of the cervix.
II. To determine the frequency of patients who survive progression-free for at least 6 months after initiating therapy or have objective tumor response.
I. To characterize the distribution of progression-free survival and overall survival.
II. To determine the effect of cetuximab on the duration of objective response in persistent or recurrent carcinoma of the cervix.
III. To determine the nature and degree of toxicity of cetuximab as assessed by CTCAE v3.0 in this cohort of patients.
Patients receive cetuximab IV over 120 minutes on day 1. Courses repeat once weekly in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed (with physical exams and histories) every three months for the first two years and then every six months for the next three years.